1. Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol 2015;7:1788-1796.
2. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45.
3. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:39-40.
4. Day C, James O. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842-845.
5. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016;13:412-425.
6. Li L, Zhang XJ, Lan Y, Xu L, Zhang XZ, Wang HH. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule. Chin J Integr Med 2010;16:23-27.
7. Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, Aoyama T. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol 2009;50:1236-1246.
8. Karaman A, Demirbilek S. Protective effect of polyunsaturated phosphatidylcholine on liver damage induced by biliary obstruction in rats. Journal of Pediatric Surgery 2003;38:1341-1347.
9. Hiroko I, Kazuhiko S, Shunichi M. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp Pathol 2013;6(12):2683-2696.
10. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40:47-51.
11. Cabrera D, Wree A, Povero D, Solis N, Hernandez A, Pizarro M, Moshage H, et al. Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis. Sci Rep 2017;7:3491.
12. Tolbol KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Schonberger T, Gillum MP, et al. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Dig Dis Sci 2019;64:1238-1256.
13. Deng P HJ, Petriello MC. Dietary inulin decreases circulating ceramides by
478 suppressing neutral sphingomyelinase expression and activity in mice. J Lipid Res 2020;61:47-51.
14. Tsugawa H, Cajka T, Kind T, Ma Y, Higgins B, Ikeda K, Kanazawa M, et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat Methods 2015;12:523-526.
15. Tsugawa H, Ikeda K, Takahashi M, Satoh A, Mori Y, Uchino H, Okahashi N, et al. A lipidome atlas in MS-DIAL 4. Nat Biotechnol 2020;38:1159-1163.
16. Abdollahi-Basir MH, Shirini F, Tajik H, Ghasemzadeh MA. Zn (BDC)-(MOF): Introduction of a New Catalyst for the Synthesis Pyrimido[4,5-d]Pyrimidine Derivatives under Ultrasound Irradiation in the Absence of Solvent. Polycyclic Aromatic Compounds 2019.
17. Kulinski A, Vance DE, Vance JE. A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem 2004;279:23916-23924.
18. Miyaki T, Nojiri S, Shinkai N, Kusakabe A, Matsuura K, Iio E, Takahashi S, et al. Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatol Res 2011;41:375-385.
19. Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh) 2019;6:1801585.
20. Lieber C. Pathogenesis and treatment of alcoholic liver disease: progress over the last 50 years. Rocz Akad Med Bialymst 2005;5:7:20.
21. Seitz HK, Lieber CS, Stickel F, Salaspuro M, Schlemmer HP, Horie Y. Alcoholic liver disease: from pathophysiology to therapy. Alcohol Clin Exp Res 2005;29:1276-1281.
22. Li Z, Vance DE. Phosphatidylcholine and choline homeostasis. J Lipid Res 2008;49:1187-1194.
23. Houten SM, Wanders RJA, Ranea-Robles P. Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. Biochim Biophys Acta Mol Basis Dis 2020;1866:165720.
24. Savic D, Hodson L, Neubauer S, Pavlides M. The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12.
25. El-Sheikh H, El-Haggar S, Elbedewy TJD, syndrome m. Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients. 2019;13:167-173.
26. Xu Y, Jiang W, Chen G, Zhu W, Ding W, Ge Z, Tan Y, et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. 2017;26:333-338.
27. Xu Y, Leo MA, Lieber CS. DLPC attenuates alcohol-induced cytotoxicity in HepG2 cells expressing CYP2E1. Alcohol Alcohol 2005;40:172-175.
28. Katz GG, Shear NH. Signaling for ethanol-induced apoptosis and repair in vitro. Clinical Biochemistry 2001;34:219-227.
29. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Krakoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011;94:58-65.
30. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
31. Yokota A, Fukiya S, Islam KB, Ooka T, Ogura Y, Hayashi T, Hagio M, et al. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes 2012;3:455-459.
32. Joghataei M, Shahidi F, Pouladfar G, Mortazavi SA, Ghaderi A. Probiotic potential comparison of Lactobacillus strains isolated from Iranian traditional food products and human feces with standard probiotic strains. J Sci Food Agric 2019;99:6680-6688.
33. Wang Y, Li A, Zhang L, Waqas M, Mehmood K, Iqbal M, Muyou C, et al. Probiotic potential of Lactobacillus on the intestinal microflora against Escherichia coli induced mice model through high-throughput sequencing. Microb Pathog 2019;137:103760.
34. Jiang J, Feng N, Zhang C, Liu F, Zhao J, Zhang H, Zhai Q, et al. Lactobacillus reuteri A9 and Lactobacillus mucosae A13 isolated from Chinese superlongevity people modulate lipid metabolism in a hypercholesterolemia rat model. FEMS Microbiol Lett 2019;366.
35. Vincent Wai-Sun Wong, Wong GL-H. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. annals of hepatology 2013;12:256-262.
36. Zhang M, Wang C, Wang C, Zhao H, Zhao C, Chen Y, Wang Y, et al. Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease. J Nutr Biochem 2015;26:337-344.